Recent Quotes (30 days)

You have no recent quotes
chg | %

Verisante Technology Inc  

(Public, CVE:VRS)   Watch this stock  
Find more results for CVE:THZ
0.405
-0.005 (-1.22%)
May 21 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.38 - 0.41
52 week 0.37 - 0.64
Open 0.41
Vol / Avg. 99,497.00/99,649.00
Mkt cap 26.37M
P/E     -
Div/yield     -
EPS -0.05
Shares 65.10M
Beta 0.78
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin - -157822.20%
Operating margin - -159568.90%
EBITD margin - -146380.40%
Return on average assets -38.40% -69.03%
Return on average equity -39.56% -75.21%
Employees 8 -
Carbon Disclosure Rating - -

Address

Suite 306, 2309 West 41st Avenue
VANCOUVER, BC V6M 2A3
Canada
+1-604-6050507 (Phone)
+1-604-6050508 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Verisante Technology, Inc. (Verisante), formerly T-Ray Science, Inc., is a medical device company. The Company focuses in the commercialization of systems for the early detection of cancer. The Company�s device Verisante Aura is used for the detection of all forms of skin cancer, including basal cell carcinoma, squamous cell carcinoma and melanoma. The Company's product portfolios include Verisante Aura and Verisante Core. Verisante Aura is an imaging and spectroscopy system designed to aid in the detection of skin cancer. Verisante Core uses an endoscopic attachment to aid in the detection of lung, colon, cervical and other cancers. Verisante Core series, detects spectral bio-markers for cancer.

Officers and directors

Thomas A. Braun President, Chief Executive Officer, Chief Business Development Officer, Director
Anna Trinh Chief Financial Officer, Vice President - Administration, Corporate Counsel, Secretary
Joseph Biegel Independent Director
Karen Boodram Independent Director
Age: 49
Christopher John Wesley Dennis Independent Director
Jake J. Thiessen Ph.D. Independent Director
Age: 66